Runxin Biotechnology

Runxin Biotechnology is a clinical-stage biopharmaceutical company based in Suzhou, China, focused on the discovery and development of innovative small molecule therapeutics for oncology. The company's research strategy centers on targeting critical signaling pathways involved in tumor growth and survival. Its lead clinical candidate, RX-208, is a potent and selective BRAF V600E inhibitor currently undergoing pivotal clinical trials for BRAF-mutated colorectal cancer and other solid tumors. Runxin's pipeline also features RX-108, a first-in-class Na+/K+-ATPase inhibitor, and RX-518, a MET inhibitor targeting non-small cell lung cancer. By leveraging its internal medicinal chemistry expertise and establishing strategic collaborations with partners like Betta Pharmaceuticals, Runxin aims to deliver effective targeted therapies to cancer patients globally.